[go: up one dir, main page]

MA54538A - Inhibiteurs d'apol1 et leurs procédés d'utilisation - Google Patents

Inhibiteurs d'apol1 et leurs procédés d'utilisation

Info

Publication number
MA54538A
MA54538A MA054538A MA54538A MA54538A MA 54538 A MA54538 A MA 54538A MA 054538 A MA054538 A MA 054538A MA 54538 A MA54538 A MA 54538A MA 54538 A MA54538 A MA 54538A
Authority
MA
Morocco
Prior art keywords
apol1
inhibitors
methods
apol1 inhibitors
Prior art date
Application number
MA054538A
Other languages
English (en)
Inventor
Michael Brodney
Jingrong Cao
Jon H Come
Leslie A Dakin
Francois Denis
Warren A Dorsch
Anne Fortier
Kevin Gagnon
Martine Hamel
Kan-Nian Hu
Elaine B Krueger
Brian Ledford
Ales Medek
Suganthini S Nanthakumar
Olivier Nicolas
Peter Rose
Camil Sayegh
Timothy J Senter
Yi Shi
Muna Shrestha
Tiansheng Wang
Faith Witkos
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MA54538A publication Critical patent/MA54538A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids [R2POH], [R2P(= O)H]: Thiophosphinous acids including[R2PSH]; [R2P(=S)H]; Aminophosphines [R2PNH2]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MA054538A 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation MA54538A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17

Publications (1)

Publication Number Publication Date
MA54538A true MA54538A (fr) 2021-10-27

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054538A MA54538A (fr) 2018-12-17 2019-12-17 Inhibiteurs d'apol1 et leurs procédés d'utilisation

Country Status (25)

Country Link
US (3) US11618746B2 (fr)
EP (1) EP3897833A1 (fr)
JP (1) JP7573528B2 (fr)
KR (1) KR20210116483A (fr)
CN (1) CN113453760B (fr)
AR (1) AR116913A1 (fr)
AU (1) AU2019405477A1 (fr)
BR (1) BR112021011564A2 (fr)
CA (1) CA3121910A1 (fr)
CL (1) CL2021001561A1 (fr)
CO (1) CO2021009053A2 (fr)
CR (1) CR20210383A (fr)
DO (1) DOP2021000116A (fr)
EC (1) ECSP21052184A (fr)
IL (1) IL283592A (fr)
JO (3) JOP20210130A1 (fr)
MA (1) MA54538A (fr)
MX (1) MX2021007152A (fr)
PE (1) PE20212302A1 (fr)
SA (1) SA521422270B1 (fr)
SG (1) SG11202105769XA (fr)
TW (1) TWI848031B (fr)
UA (1) UA128375C2 (fr)
UY (1) UY38514A (fr)
WO (1) WO2020131807A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212302A1 (es) 2018-12-17 2021-12-10 Vertex Pharma Inhibidores de apol1 y sus metodos de uso
CN116348447A (zh) * 2020-01-29 2023-06-27 弗特克斯药品有限公司 Apol1的抑制剂及其使用其的方法
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
AU2021230562A1 (en) * 2020-03-06 2022-09-22 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
US20230250087A1 (en) * 2020-06-12 2023-08-10 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
PE20231106A1 (es) 2020-08-26 2023-07-19 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos
IL305026A (en) * 2021-02-19 2023-10-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use
MX2024002229A (es) * 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
WO2023101981A1 (fr) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Inhibiteurs spirocycliques d'apol1 et procédés d'utilisationde ceux-ci
IL314330A (en) 2022-01-18 2024-09-01 Maze Therapeutics Inc Apol1 inhibitors and methods of use
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法
WO2023194895A1 (fr) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Dérivés pyrroliques utilisés en tant qu'inhibiteurs de l'apolipoprotéine l-1
WO2024040235A1 (fr) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Inhibiteurs d'apol1 et procédés d'utilisation

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
EP0934941A1 (fr) 1996-08-09 1999-08-11 Eisai Co., Ltd. Derives de benzopiperidine
WO1999032482A1 (fr) 1997-12-19 1999-07-01 Eli Lilly And Company Composes d'imidazoline hypoglycemiques
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001017965A2 (fr) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
KR20050044450A (ko) 2001-11-14 2005-05-12 테바 파마슈티컬 인더스트리즈 리미티드 로사르탄 칼륨의 무정형 및 결정형 형태 및 이의 제조 방법
WO2003104180A1 (fr) * 2002-06-05 2003-12-18 Natco Pharma Limited Procede de preparation d'acide 4-(4-fluorobenzoyl) butyrique
ES2361924T3 (es) 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
JP2007504221A (ja) 2003-09-03 2007-03-01 ガラパゴス・エヌブイ 新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用
JP2007526304A (ja) 2004-03-03 2007-09-13 イーライ リリー アンド カンパニー 二環式置換インドール誘導体ステロイドホルモン核内受容体モジュレータ
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
AU2006316321A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2666406A1 (fr) 2006-10-16 2008-04-24 Gruenenthal Gmbh Derives de sulfonamide substitues en tant que modulateurs du recepteur de bradykinine-1
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
EP2118074B1 (fr) * 2007-02-01 2014-01-22 Resverlogix Corp. Composés destinés à la prévention et au traitement de maladies cardiovasculaires
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
WO2009025478A1 (fr) 2007-08-17 2009-02-26 Lg Life Sciences Ltd. Composés d'indole et d'indazole en tant qu'inhibiteurs de nécrose cellulaire
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
KR101368130B1 (ko) 2009-11-16 2014-02-27 일라이 릴리 앤드 캄파니 Ｏｒｌ―１ 수용체 길항제로서의 스피로피페리딘 화합물
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2012025155A1 (fr) 2010-08-26 2012-03-01 Novartis Ag Composés à base d'hydroxamate en tant qu'inhibiteurs des désacétylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP3049405A4 (fr) * 2013-09-26 2017-03-08 Pharmakea Inc. Composés inhibiteurs de l'autotaxine
EP3122726B1 (fr) 2014-03-27 2018-08-29 Academisch Medisch Centrum Iminosucres n-(5-((aryl ou hétéroaryl)méthyloxy)pentyl)-substitués comme inhibiteurs de glucosylcéramide synthase
CA2959437C (fr) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Modulateurs du recepteur cannabinoide de type 1
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
MX2017006437A (es) 2014-11-21 2017-08-08 Esteve Labor Dr Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
RU2684324C1 (ru) 2015-08-27 2019-04-08 Пфайзер Инк. Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
JP6990657B2 (ja) 2016-02-08 2022-01-13 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｄｄｒ１阻害剤としてのスピロインドリノン
EP3787669A4 (fr) 2018-04-30 2022-03-30 The Trustees of Indiana University Composés destinés à moduler les niveaux de ddah et d'adma, ainsi que leurs méthodes d'utilisation pour traiter une maladie
PE20211397A1 (es) 2018-05-22 2021-07-27 Ionis Pharmaceuticals Inc Moduladores de la expresion de apol1
PE20212302A1 (es) 2018-12-17 2021-12-10 Vertex Pharma Inhibidores de apol1 y sus metodos de uso
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
JP2023508930A (ja) 2019-12-19 2023-03-06 カスマ セラピューティクス， インコーポレイテッド Ｔｒｐｍｌモジュレーター
CN116348447A (zh) 2020-01-29 2023-06-27 弗特克斯药品有限公司 Apol1的抑制剂及其使用其的方法
US20210246121A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
AU2021230562A1 (en) 2020-03-06 2022-09-22 Vertex Pharmaceuticals Incorporated Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
JP2023523176A (ja) 2020-04-22 2023-06-02 アニマ バイオテック インコーポレイテッド コラーゲン１翻訳阻害剤及びその使用方法
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
CN115884965A (zh) 2020-05-07 2023-03-31 拉姆巴姆医疗技术有限公司 用于治疗ApoL1相关疾病的组合物
US20230011118A1 (en) 2020-06-12 2023-01-12 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
US20230250087A1 (en) 2020-06-12 2023-08-10 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3185144A1 (fr) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibiteurs d'apol1 et leur utilisation
PE20231106A1 (es) 2020-08-26 2023-07-19 Vertex Pharma Inhibidores de apol1 y metodos para usar los mismos
MX2024002229A (es) 2021-08-26 2024-05-15 Vertex Pharma Formas solidas de inhibidores de apolipoproteina l1 (apol1) espirotriciclicos y metodos de uso de las mismas.
WO2023101981A1 (fr) 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Inhibiteurs spirocycliques d'apol1 et procédés d'utilisationde ceux-ci
US20230203000A1 (en) 2021-11-30 2023-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN119013281A (zh) 2022-02-08 2024-11-22 弗特克斯药品有限公司 作为apol1抑制剂的4'，5'-二氢螺[哌啶-4，7'-噻吩并[2，3-c]吡喃]衍生物和其使用方法
WO2023154314A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de spiro pipéridine utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
WO2023154310A1 (fr) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4-phénylpipéridin-4-ol utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation
CN119343353A (zh) 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Also Published As

Publication number Publication date
US20200377479A1 (en) 2020-12-03
EP3897833A1 (fr) 2021-10-27
CA3121910A1 (fr) 2020-06-25
DOP2021000116A (es) 2021-09-30
CN113453760A (zh) 2021-09-28
IL283592A (en) 2021-07-29
SA521422270B1 (ar) 2024-02-18
JOP20210131A1 (ar) 2023-01-30
MX2021007152A (es) 2021-11-03
WO2020131807A1 (fr) 2020-06-25
JP2022515369A (ja) 2022-02-18
PE20212302A1 (es) 2021-12-10
CO2021009053A2 (es) 2021-08-09
KR20210116483A (ko) 2021-09-27
SG11202105769XA (en) 2021-07-29
ECSP21052184A (es) 2021-08-31
UY38514A (es) 2020-07-31
US20250042878A1 (en) 2025-02-06
CN113453760B (zh) 2024-05-24
AU2019405477A1 (en) 2021-06-24
JP7573528B2 (ja) 2024-10-25
US20230271945A1 (en) 2023-08-31
US12060346B2 (en) 2024-08-13
CL2021001561A1 (es) 2021-11-26
CR20210383A (es) 2021-09-22
JOP20210130A1 (ar) 2023-01-30
BR112021011564A2 (pt) 2021-08-31
TW202039471A (zh) 2020-11-01
UA128375C2 (uk) 2024-06-26
US11618746B2 (en) 2023-04-04
AR116913A1 (es) 2021-06-23
TWI848031B (zh) 2024-07-11
JOP20210129A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3515916C0 (fr) Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
MA51848A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA52765A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52501A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52496A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA54758A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA55301A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
MA50912A (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
MA55381A (fr) Pyridazinones et leurs procédés d'utilisation
EP3635000A4 (fr) Manabodies et procédés d'utilisation
EP3897622A4 (fr) Inhibiteurs d'arginase et procédés d'utilisation